Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.
about
Continuous internal counterpulsation as a bridge to recovery in acute and chronic heart failureEndpoints in stem cell trials in ischemic heart failureMitral valve repair versus replacementCardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunctionReverse Cardiac Remodeling: A Marker of Better Prognosis in Heart FailureTwo-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral RegurgitationMitral-valve repair versus replacement for severe ischemic mitral regurgitation.Risk-benefit assessment of ivabradine in the treatment of chronic heart failureHeart failure with recovered ejection fraction: clinical description, biomarkers, and outcomesRethinking Phase II Clinical Trial Design in Heart Failure.Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF.Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy.The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse.Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at higNovel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide.Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography: a feasibility studyLeft ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study.Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Macrophage activation and polarization in post-infarction cardiac remodeling.Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.Cardiac inotropes: current agents and future directions.Myocardial recovery and the failing heart: myth, magic, or molecular target?Concise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical Applications.Epidemiology of "Heart Failure with Recovered Ejection Fraction": What do we do After Recovery?Abnormal Global Longitudinal Strain Predicts Future Deterioration of Left Ventricular Function in Heart Failure Patients With a Recovered Left Ventricular Ejection Fraction.Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.Impact of QT interval prolongation following antiarrhythmic drug therapy on left ventricular function.The Role for Cardiovascular Remodeling in Cardiovascular Outcomes.Echocardiographic Predictors of Long-Term Survival in Patients Undergoing Cardiac Resynchronization Therapy: What Is the Optimal Metric?Combined biomarker testing for the prediction of left ventricular remodelling in ST-elevation myocardial infarction.Cardiac Resynchronisation Therapy or MitraClip® Implantation for Patients with Severe Mitral Regurgitation and Left Bundle Branch Block?Myocardial remodelling and recovery in dilated cardiomyopathy.Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling.Identification of high-risk chronic heart failure patients in clinical practice: role of changes in left ventricular function.Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.
P2860
Q26751457-BDBC151B-C8F5-4E84-BE3F-C6DAF4EA4972Q26796330-3C01ECAD-4D8D-4871-98FE-6848ACD3E5DCQ26796736-ABB904A2-6E2F-47DA-AE02-FAC726F49946Q27002918-5BEEFEBD-57DF-49D4-95AA-DD5CAF8FD0D8Q28264330-6CA5C48A-C425-450A-A8B3-3003405BFAFAQ30278369-1B9FD42E-6DC7-4DBD-B5EC-D58F4692C8E4Q30411350-A3F16B55-874C-4E83-BC40-C4EC59470E9DQ33568592-5013D3B2-FCFB-4FE2-9E00-47E673D40FA2Q33740885-7BD64D02-2D21-497F-9640-50085C85CDF8Q34377514-80CDDAEA-B030-4A27-8D5D-076135571DADQ34631911-3A6B6929-694E-4A00-8413-0ACCB05CE850Q34891236-D35FE36E-6B3C-4C4E-AAC7-393CD979455BQ35224187-97D68FB2-6151-4C4D-9E8F-5AA4F80135F8Q35335608-857D2289-B43D-49DA-B814-61FD7EA115E4Q35621283-3F62329A-4903-405A-A2EA-4284566B0DBBQ36011869-EAD33E2A-BF7E-4AC8-BFFA-A45B044D7EC0Q36156912-A8E8B768-2EAC-4E0E-A1A6-D5295A9E07B8Q36564032-33C5B266-4CA3-4113-82D1-DEC905ACA232Q36859256-6D62D86E-F5D7-4219-B183-E30A53A5A7E4Q36868978-9C9EA49B-0E6A-40AC-BDED-603AC22CFFFAQ36881933-7D5D18FC-1F76-4684-A8DE-BD6E8E8893A6Q37016190-F20D2602-9C61-4E25-9B93-D5D51463ADD1Q37097189-3DD92D6E-DFEE-4532-AC65-160EA47ABFE0Q37630894-4B6526F7-86E1-4A63-88F1-157058CD6633Q37738591-DE3889AD-4752-41D9-9C73-BD06E0355B55Q37851240-59A41DE9-89A3-41A5-A149-F96EB4342CBFQ38060345-817B2895-80A8-4163-B36B-E8BB36687648Q38610604-4F20314C-457E-4AEA-BC31-5ABDB90FA62BQ38612603-2808135E-853B-4ED8-B449-E8B507489DACQ38677002-FE92C417-C326-47A2-ABB1-7F969F09F738Q38737940-976857A2-A271-4A76-8556-241900130E76Q38780988-0D21015C-08DC-4F6E-BBCE-7332A9AB7A9DQ38867740-3D1B7945-9D60-410F-8011-BC6CCF5037E8Q38972851-3FD4986F-773E-4A55-A887-B2746785B478Q39293604-12729318-AA6E-41F6-8F86-E9C6558FCB68Q40033359-776F3A4D-93E0-471A-A888-E2B353779FECQ42375572-F6684659-3797-4770-BD54-ED702711601FQ42719037-AE094C2F-8875-45E6-B48C-D7CE6566D4B5Q43907909-70D4C544-C535-426A-9DB6-0AD0CED85177Q45237005-252A1DA4-9E5C-4C2E-B493-DC6733791AEA
P2860
Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Quantitative evaluation of dru ...... ion: a meta-analytic approach.
@en
type
label
Quantitative evaluation of dru ...... ion: a meta-analytic approach.
@en
prefLabel
Quantitative evaluation of dru ...... ion: a meta-analytic approach.
@en
P2093
P2860
P1476
Quantitative evaluation of dru ...... ion: a meta-analytic approach.
@en
P2093
Daniel G Kramer
David M Kent
George V Antonopoulos
James E Udelson
Marvin A Konstam
Thomas A Trikalinos
P2860
P304
P356
10.1016/J.JACC.2010.05.011
P407
P577
2010-07-01T00:00:00Z